Alumni Event: Fireside Chat with a seasoned BD Executive

2:00–6:00 pm

Feb.
6

On February 6, Dr. Jun Bao, MBA’99, had an interesting dialogue on business development in biomedicine with Clifford Stocks who also holds an MBA from the Booth School of Business, in front of an enthusiastic audience gathered at the University of Chicago Center in Beijing. 


Clifford J. Stocks is the Founder and Chief Executive Officer of OncoResponse, Inc., a Seattle based biotech company focused on immuno-oncology which was formed through a strategic alliance between Theraclone Sciences and MD Anderson Cancer Center.  Recently he was CEO of Theraclone where he oversaw the successful development of several therapeutic antibodies focused on infectious diseases, including monoclonal antibodies, for HIV-cure licensed to Gilead. Mr. Stocks’ career includes 15 years at ICOS corporation, where he served as an Executive Officer and Vice President of Business Development.  He was a key architect of the Lilly ICOS joint venture partnership leading to their $2.3 billion merger in 2007.  His early career includes academic research on staff in the department of molecular genetics and cell biology at the University of Chicago, where he received his MBA from.


50 people from research institutions, manufacturers, sales companies, consulting firms, universities, law firms, and financial and insurance companies attended the event.  The dialogue helped the audience to further understand the strategies and skills needed in business development of the biomedicine industry. 


Jun Bao, MBA’99, PhD, is Senior Vice President and Chief Business Officer, Acting Chief Financial Officer, Member of Board of Directors of the Beijing Shenogen Biomedical Co., Ltd.


The event was co-organized by the Tongxieyi Club, University of Chicago Beijing Alumni Club and the BayHelix Group.


2017年2月6日,由同写意BD俱乐部、芝加哥大学校友会和百华协会共同举办的2017年第一场BD和投资沙龙活动在芝加哥大学北京中心举办。本次活动围绕包骏博士对Clifford Stocks先生以BD和医药产业发展为主题的现场采访展开。


Clifford是全球知名的BD专家,曾在芝加哥大学从事分子基因和细胞生物学研究,并获布斯商学院MBA。他在20多年的BD生涯中,设计和实施了多种BD的交易,其中最为著名的是礼来和ICOS的JV。


50余名来自各研发机构、生产企业、销售企业、咨询机构、高校、法律界、金融保险机构的与会者共聚一堂,通过讨论提问交流等环节让大家对生物医药产业BD的策略和实施技巧有了更深程度的理解。


作为BD职业人必备的素质与修养,与会者均从此次活动中了解到了更多关于生物医药产业BD的策略与实施技巧,并通过此次聚会对产业信息与心得进行了更深层次的交流。希望未来能有更多BD人才加入到同写意BD俱乐部中来。


包骏博士于1999年获芝加哥大学布斯商学院MBA学位,现任珅奥基医药科技资深副总裁兼首席商务官。